title: Immunotherapy for Alzheimer's disease: past, present and future.
abstract: Alzheimer's disease (AD) is an incurable, progressive, neurodegenerative disorder affecting over 5 million people in the US alone. This neurological disorder is characterized by widespread neurodegeneration throughout the association cortex and limbic system caused by deposition of Aβ resulting in the formation of plaques and tau resulting in the formation of neurofibrillary tangles. Active immunization for Aβ showed promise in animal models of AD; however, the models were unable to predict the off-target immune effects in human patients. A few patients in the initial trial suffered cerebral meningoencephalitis. Recently, passive immunization has shown promise in the lab with less chance of off-target immune effects. Several trials have attempted using passive immunization for Aβ, but again, positive end points have been elusive. The next generation of immunotherapy for AD may involve the marriage of anti-Aβ antibodies with technology aimed at improving transport across the blood-brain barrier (BBB). Receptor mediated transport of antibodies may increase CNS exposure and improve the therapeutic index in the clinic.
authors: Department of Neurosciences, University of California San Diego, La Jolla, CA, USA.
authors: Brian
authors: B
authors: Spencer
authors: Department of Neurosciences, University of California San Diego, La Jolla, CA, USA ; Department of Pathology, University of California San Diego, La Jolla, CA, USA.
authors: Eliezer
authors: E
authors: Masliah
keywords: Alzheimer’s disease; Aβ; blood-brain barrier; immunization; immunotherapy